Literature DB >> 20725055

Pressor responses to antihypertensive drug types.

Michael H Alderman1, Hillel W Cohen, Jean E Sealey, John H Laragh.   

Abstract

BACKGROUND: Pressor responses to antihypertensive drugs are not addressed in treatment guidelines although they have been described in various clinical situations. We now report the incidence of pressor responses to initiation of monotherapy using four antihypertensive drug types, and the influence of plasma renin activity (PRA) status, among participants in a worksite-based antihypertensive treatment program.
METHODS: Systolic blood pressure (SBP) response was evaluated among 945 participants with no prior treatment who were given either a diuretic or calcium-channel blocker (natriuretic antivolume V drugs, n = 537) or a beta-blocker or angiotensin-converting enzyme (ACE) inhibitor (antirenin R drugs n = 408). PRA was categorized by low, middle, and high tertiles (L, M, and H). SBP rise > or =10 mm Hg was considered pressor.
RESULTS: More pressor responses occurred with R than V drugs (11% vs. 5%, P = 0.001). L, M, and H renin tertiles had similar frequencies with V drugs (6, 4, and 6%), but low and middle tertiles given R had greater pressor frequencies (17% P = 0.003 vs. V and 10% P = 0.02 vs. V). Treatment SBP > or =160 mm Hg occurred more frequently with R than V drugs (19% vs. 13%; P = 0.007); moreover, in the lowest renin tertile 35% R vs. 13% V (P = 0.001) had SBP > or =160 mm Hg. Treatment SBP <130 mm Hg was more frequent in V patients in the lowest tertile (18% vs. 5%; P = 0.003), and in R patients in the highest tertile (26% vs. 12%, P = 0.002).
CONCLUSIONS: Pressor responses to antihypertensive monotherapy occur sufficiently frequently to be of concern, especially in lower renin patients given a beta-blocker or ACE inhibitor (ACEI).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20725055     DOI: 10.1038/ajh.2010.114

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  12 in total

1.  Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Activated intrarenal renin-angiotensin system is correlated with high blood pressure in humans.

Authors:  Hiroyuki Kobori; Qi Fu; Steven D Crowley; Romer A Gonzalez-Villalobos; Ruy R Campos
Journal:  J Appl Physiol (1985)       Date:  2010-12

2.  Assessing the associations of sodium intake with long-term all-cause and cardiovascular mortality in a hypertensive cohort.

Authors:  Pamela Singer; Hillel Cohen; Michael Alderman
Journal:  Am J Hypertens       Date:  2014-08-26       Impact factor: 2.689

Review 3.  Personalized vascular medicine: individualizing drug therapy.

Authors:  Emil M Degoma; Giovanni Rivera; Scott M Lilly; M Haris U Usman; Emile R Mohler
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

Review 4.  Resistant Hypertension: A Real Entity Requiring Special Treatment?

Authors:  Stefano Taddei; Rosa Maria Bruno
Journal:  Eur Cardiol       Date:  2016-08

Review 5.  Plasma renin testing to guide antihypertensive therapy.

Authors:  Anthony J Viera; Curt D Furberg
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

Review 6.  Rational use of antihypertensive medications in children.

Authors:  Michael A Ferguson; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2013-05-29       Impact factor: 3.714

7.  Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.

Authors:  Stephen T Turner; Kent R Bailey; Gary L Schwartz; Arlene B Chapman; High Seng Chai; Eric Boerwinkle
Journal:  Hypertension       Date:  2012-05-07       Impact factor: 10.190

8.  Resistant Hypertension: A Real Entity or a Phantom Diagnosis?

Authors:  Costas Thomopoulos; George Skalis; Thomas Makris
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-04-17       Impact factor: 3.738

9.  Association Between Polymorphisms of ADRBK1 Gene and Plasma Renin Activity in Hypertensive Patients: A Case-Control Study.

Authors:  Yu Li; Nanfang Li; Xiaoguang Yao; Mulalibieke Heizati; Delian Zhang; Qing Zhu; Guijuan Chang; Xiangyang Zhang
Journal:  Med Sci Monit       Date:  2016-08-24

10.  Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure.

Authors:  Simran K Bhandari; Michael Batech; Jiaxiao Shi; Steven J Jacobsen; John J Sim
Journal:  Kidney Res Clin Pract       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.